SCHEDULE 13D/A: Matrix Capital Management Discloses 11.17% Stake in Aura Biosciences and Enters 90-Day Lock-Up Agreement Post-Offering

Matrix Capital Management Company LP and David E. Goel have filed an amended Schedule 13D, disclosing a beneficial ownership of 11.17% in Aura Biosciences, Inc. and confirming a 90-day lock-up agreement following the company's recent 2025 Offering.

Summary

• Matrix Capital Management Company LP and David E. Goel collectively beneficially own 6,922,870 shares of Aura Biosciences, Inc. Common Stock.
• This ownership represents 11.17% of the total outstanding Common Stock.
• The percentage is calculated based on 61,960,877 shares outstanding after the completion of the 2025 Offering.
• In connection with the 2025 Offering, Matrix Fund entered into a lock-up agreement with the underwriters on May 16, 2025.
• The lock-up agreement restricts the sale or transfer of shares or convertible securities for 90 days after the date of the Underwriting Agreement related to the 2025 Offering.

Sentiment

Score: 7

Explanation: The document is primarily a factual regulatory filing. The disclosure of a significant stake by a major investor and the entry into a lock-up agreement post-offering can be viewed positively as it signals commitment and reduces immediate selling pressure, contributing to market stability.

Positives

• The significant beneficial ownership of 11.17% by Matrix Capital Management and David E. Goel indicates a substantial investment and potential long-term commitment to Aura Biosciences.
• The 90-day lock-up agreement entered into by Matrix Fund following the 2025 Offering suggests stability by preventing immediate selling pressure from a major shareholder post-issuance.

Negatives

• The lock-up agreement restricts the reporting person's ability to sell or transfer shares for 90 days, limiting their liquidity during this period.

Risks

• The reporting person is subject to a 90-day lock-up agreement, restricting their ability to sell or transfer their shares of Common Stock or related securities.

Future Outlook

The lock-up agreement indicates that Matrix Capital Management will be restricted from selling or transferring its shares in Aura Biosciences for 90 days following the 2025 Offering, suggesting a period of stability for this significant shareholder's position.

Industry Context

This Schedule 13D amendment reflects a significant institutional investor's continued substantial stake in a biotechnology company following a capital raise. Such filings are common in the biotech sector where companies frequently raise capital to fund research and development, and institutional investors play a crucial role in providing that capital and often hold long-term positions.

Stakeholder Impact

• Shareholders: The lock-up agreement by a significant investor may provide a degree of stability to the stock price by preventing immediate large-scale selling post-offering. The continued significant ownership by Matrix Capital Management could be seen as a vote of confidence.

Next Steps

• The lock-up agreement will expire on the 90th day after the date of the Underwriting Agreement entered into by the Issuer in connection with the 2025 Offering.

Key Dates

Keywords

Aura Biosciences, Matrix Capital Management, Schedule 13D, Beneficial Ownership, Lock-up Agreement, Common Stock, SEC Filing, Institutional Investor, Equity Offering